The US stock market surged on Friday, with the S&P 500 recording its biggest daily gain since early March, and the OTCQX Composite, which tracks over 400 OTC stocks, surging to the highest since mid-September. The worries that the Fed would be forced to increase the interest rates earlier than anticipated were faded away by the labor market and inflation data.
The jobless claims fell last week to the lowest in 19 months, which supported investor sentiment. Also, producer prices eased last month.
Alan Lancz, president at Alan B. Lancz & Associates, told Reuters:
“Some of the things that worried the market in September, and even last week, as far as the inflation aspect and higher interest rates and the Delta variant, maybe have lessened. Not that it’s all over, but on a temporary scale at least, you can make a case for it trending in the right direction.”
The stock market had a difficult period in September, pulling back from the record highs. Nevertheless, that correction was needed, and now we can think of another bullish run. There are many good OTC stocks performing well during good days like this, and our job is to identify the best opportunities.
OTC STOCKS THE PLACE TO BE
Smart investors know that if you want to make the big money off a small account, the place to be is the OTC Markets. There are many good OTC stocks that can boost your portfolio’s value in the long term. For investors, we preach the key to trading penny stocks is finding momentum BEFORE it happens and ahead of the crowd.
We alert our subscribers with our best ideas before our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here.
If you watch the Insider Financial YouTube channel, you can get a sense of the ideal time to book profits. We warned our subscribers not to get greedy or get caught up in the diamond hands/paper hands BS.
We also recommend you own a portfolio of penny stocks. For some, that can be as many as 10 to 20 or more OTC stocks. This provides diversification and allows one to manage the market’s moods much easier. It also helps to own shares in the following 4 hot OTC stocks.
In this article, we look at 4 OTC stock that will greatly reward patient investors. They are Majic Wheels Corp (OTCPK: MJWL), Net Savings Link, Inc (OTCPK: NSAV), Telco Cuba, Inc (OTCPK: QBAN), and Todos Medical Ltd (OTCQB: TOMDF).
OTC STOCK #1 MJWL
Majic Wheels Corp didn’t perform quite well during the August-September period, but we insisted it was a great opportunity to buy the dip, and today this crypto play is confirming what was clear for us – Majic has strong fundamentals and is tapping into the fastest-growing market, so it has to perform well sooner than later. The share price has increased by about 50% since last week, currently trading at $0.13, which is the highest since the beginning of August.
Majic peaked at the beginning of July at over $0.25, surging over 13,000% since the beginning of the year. We presented our bullish case for MJWL in May when the OTC stock was trading at only $.014 a share.
The company has focused on the fintech and software markets after dumping its waste management business.
We reported previously that MJWL had acquired CGCX Ltd, a cryptocurrency exchange and custody service platform generating $150 million in revenue. In April, CGCX launched its first insured over-the-counter (OTC) crypto trading desk in India, offering traders a direct medium of exchange. Besides the India Crypto Exchange, it generates revenues from the Custody Solutions and the Crypto Mining business lines.
Earlier this month, investors started to increase their stake in MJWL after finding out that the $230 million company had signed a letter of Intent (LOI) to acquire a majority interest in Bamboo Wellness Holdings Limited. Bamboo Blockchain and Analytics Competency Center aim to create a holistic healthcare ecosystem that will drive a data-driven decision-making model. Supported by artificial intelligence (AI) and machine learning, the Bamboo ecosystem aims to drastically bridge the health protection gap and bring insurance to everyone.
According to a market size, share & trends analysis report by Grand View Research, the global insurtech market size was valued at $2.72 billion in 2020 and expected to expand at a CAGR of 48.8% from 2021 to 2028.
Besides internal factors, MJWL is benefiting from external fundamentals, as Bitcoin has surged by 5% on Thursday alone, reaching the highest level since the beginning of May at over $61,000, driven by inflation worries, more adoption from institutions, and the crypto’s endorsement from billionaire George Soros.
On Thursday, MJWL announced that it was acquiring a majority interest in PCEX, another Cryptocurrency Exchange & Trading Platform.
“The combination of Majic’s CGCX expertise and PCEX novel approach and scalable model will further Majic’s ambition to firmly establish itself as a Fintech & Technology leader in India.” said David Chong, Chief Executive Officer of Majic Wheels, Corp.
We expect MJWL to continue its bullish move, with more acquisitions to be announced soon. Look for new highs in MJWL sooner than later.
— Majic Corp (@MajicCorp) October 8, 2021
OTC STOCK #2 NSAV
Net Savings Link, Inc is another crypto play, and it has a similar market cap of $220 million. The share price has increased by about 40% since last week, peaking on Wednesday at $0.044, after which it corrected to the current level of $0.037. The share price hit a YTD high at the beginning of August at almost $0.15.
Our subscribers who got exposure to this OTC stock after our several recommendations on NSAV could secure generous profits, but the stock is ready for another bullish trend to break above the $0.1 mark again.
NSAV is among the most promising crypto runners on OTC markets. Last month, the company launched its premium over-the-counter crypto trading desk, enabling institutional investors and high-net-worth individuals (HNWIs) to trade large amounts of crypto by benefiting from discreet transactions and settlements.
Meanwhile, VirtuaBroker, which NSAV acquired a few months ago, continues to run as a crypto investment platform powered by AI and offering a full range of trading services, including portfolio management and price search function.
On top of that, the company recently launched its proprietary crypto exchange aimed at retail traders, which holds the NSAV brand name, although we’re not sure whether it’s operational. It will probably start operations within two months, subject to legal, regulatory, and licensing issues. The company’s cryptocurrency and blockchain attorney will ensure that NSAV fully complies with regulations implemented by the US Congress and the SEC.
NSAV is led by NSAV Director, Yuen Wong, who is also the CEO of LABS Group Limited – the world’s first end-to-end blockchain-powered real estate investment ecosystem. He is also a managing partner at Bitmart, a crypto exchange with 2+ million users worldwide and ranked on CoinMarketCap.
But this is not all. Besides its crypto exchange, VirtuaBroker, and OTC desk, NSAV is about to launch a decentralized crypto exchange (DEX) and have it fully operations and trading within several weeks.
At the end of last month, NSAV announced the acquisition of a 40% stake in Hong Kong premium OTC crypto trading desk HKOTC.CO, which is one of Hong Kong’s most popular OTC crypto trading services, with 16 strategic crypto and blockchain partners, including Binance, Huobi, ZB.com, and BW.com. HKOTC.CO offers fast settlement, flexible payment methods, and secure trading.
NSAV also taps into the non-fungible token (NFT) market with a partnership with LuxFi, a real-world luxury asset-backed NFT marketplace.
On top of everything, another major update came last week when NSAV hinted that it would launch crypto mining services. This will be a huge move especially after China cracked down on local miners, allowing the US to become a leader.
As the Chinese government has recently banned crypto mining, many Chinese mining companies are looking to relocate to the USA and this presents a huge opportunity for NSAV. Thank you.https://t.co/RGQg0oJl3H
— NSAV Holdings (@NSAVTech) October 8, 2021
And there is more – NSAV is currently negotiating to buy a majority stake in a well-known crypto exchange.
We have also received quite a few messages from NSAV shareholders regarding the acquisition of a majority stake in a major, existing crypto exchange, which we have been working on for months. We will have an update on that early next week.
— NSAV Holdings (@NSAVTech) October 13, 2021
The company is also working on its governance token, and more major announcements will come soon. We think this is an undervalued OTC stock that you should get right now to increase the value of your portfolio in the long term. Eventually, NSAV plans to provide a wide range of services related to software solutions, e-commerce, financial services, and information technology. This OTC stock will be huge.
OTC STOCK #3 QBAN
Telco Cuba, Inc has been on the rise, gaining over 40% since last week to trade at $0.0013. This is a bargain price for a very small company with only a $7 market cap but with great potential. The last time when we reported on QBAN, it was trading near its YTD high at $0.0023, and we still believe it has decent fundamentals to back a potential uptrend.
QBAN offers cellular services in the US and Cuba. It provides low-cost international rates plans to talk/text with and without data plans. It also offers calling plans to make international calls at similar or lower rates than landline rates, as well as direct text messaging and calling services, cell phone roaming services, and digital home phone services.
The company has three subsidiaries:
- Advanced Satellite Systems, Inc. is an Internet, Cable Television, and Telephone Service provider;
- Amgentech, Inc. is a premier provider of colocation, hosting, software development, website development and VoIP services in the South Florida region
- Naked Papers Brands, Inc. is a manufacturer, seller and marketer of clear rolling tobacco paper.
So is this a good stock to buy? Let’s begin with the fact that it has a great share structure, with the authorized shares almost maxed out. The company has acquisition targets, independent directors status (with one of the directors working at a NASDAQ-listed company), is debt-free and the number of subscribers is increasing.
The company is working to change its name to Solidus Communications. QBAN looks like a discount entry opportunity at current levels.
— HPInvest (@HPInvestor) September 28, 2021
OTC STOCK #4 TOMDF
Todos Medical Ltd is one of the stocks that we find very promising thanks to its COVID-19 treatment that may end up being quite successful in reducing potential deaths. The share price has increased by over 30% since last week to trade at $0.043, which is a strong resistance that may be broken soon. We shared an in-depth analysis of TOMDF, presenting our bullish stance.
The $40 million company, which is an OTCQB member, announced last week positive clinical validation data for its 3CL protease biomarker assay TolloTest in a clinical study evaluating its sensitivity compared with PCR in hospitalized COVID-19 patients, patients hospitalized for conditions other than COVID-19, and individuals exposed to confirmed COVID-19 subjects in the community outpatient setting and healthy controls. The trial has been conducted in collaboration with its joint venture partner NLC Pharma.
The results clinically validated the sensitivity of the 3CL protease biomarker compared with SARS-CoV-2 PCR confirmed positive results in both the hospital and outpatient setting, and provided key insights on the potential role the 3CL protease biomarker could play in assessing the COVID infectivity status of infected patients being released from quarantine and opening the diagnostic window to include earlier diagnosis of individuals from time of time known exposure. TOMDF sees multiple use cases for the 3CL protease biomarker as an adjunct to both PCR testing and antigen testing for SARS-CoV-2.
Besides the biomarker, TOMDF is working on a treatment. Earlier this month, it provided an update on its COVID-19 oral antiviral 3CL protease inhibitor Tollovir clinical development program, which is currently enrolling a Phase 2 clinical trial in hospitalized patients at Shaare Zedek Medical Center in Jerusalem, Israel. There are currently 27 patients enrolled in the 77-patient Tollovir hospitalized clinical trial in Israel. A pre-specified interim analysis of the safety and efficacy data of Tollovir is scheduled at 33 patients, which the company expects to enroll in the next several weeks. Upon enrollment completion of the course of treatment for the 33rd patient, the Tollovir DSMB will convene to review the data and decide whether continued enrollment in the clinical study is warranted. Additional clinical trial sites that currently have higher volumes of COVID patients in Israel are expected to be added to the study in order to accelerate enrollment.
Tollovir is a proprietary formulation of key plant extracts that contain potent, highly selective, natural 3CL protease inhibitor and anti-cytokine activities that make Tollovir a strong therapeutic candidate for the treatment of COVID-19. The ingredients contained within Tollovir have been deemed safe for widespread use by multiple regulatory agencies worldwide, including the US FDA, and have been used in over 5,000 human subjects since the beginning of the COVID-19 pandemic, with certain case studies previously shared publicly. Other oral antiviral drug candidates for COVID-19, such as Merck’s Molnupiravir and Pfizer’s PF-07321332, are chemical compounds that have yet to be deemed safe for widespread human use by any regulatory agency. Given the strong safety profile of Tollovir, TOMDF is confident that it provides a compelling alternative to newly created or repurposed failed chemical drug candidates that have yet to rigorously demonstrate long-term safety.
We have high expectations of TOMDF and consider it to be a great OTC stock buy with long-term potential. And you can get it for only 4 cents per share.
— Growth Stock Crack Addict (@SustainableCap3) October 12, 2021
THE FINAL NOTE
All of the 4 OTC stocks discussed today are on the rise and are good stocks to hold. Nevertheless, our best advice is to be patient and enter the market during corrections. Buying dips and selling rips as swing trades remains the best strategy in the penny stock market. Still, whenever a penny stock is in the middle of a bull run, we recommend our subscribers to book profits.
It’s very important to eye the best OTC stocks that have room for growth and have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.
Remember, all you need is one or two penny stocks to succeed in order to crush the market averages.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.